Literature DB >> 21668444

Comorbidities and predictors of health-related quality of life in Dravet syndrome.

Andreas Brunklaus1, Liam Dorris, Sameer M Zuberi.   

Abstract

PURPOSE: Health-related quality of life (HRQOL) has emerged as a widely accepted measure to evaluate how chronic disease impacts on an individual's physical, social, and mental well-being. There is a paucity of data focusing on HRQOL in specific epilepsy syndromes and their associated needs. In this study our aim was to describe the comorbidities and disease-related predictors for HRQOL in Dravet syndrome, an epileptic encephalopathy, with defined genetic etiology. We anticipate that this will help us to better recognize and understand the needs of children and families and aid treatment planning in this severe epilepsy syndrome.
METHODS: One hundred sixty-three individuals with Dravet syndrome and their families participated in the study. Detailed clinical and demographic information was available for each case. HRQOL was evaluated with two epilepsy-specific instruments, the Impact of Pediatric Epilepsy Scale (IPES) and the Epilepsy & Learning Disabilities Quality of Life Questionnaire (ELDQOL); a generic HRQOL instrument; the Pediatric Quality of Life Inventory (PedsQL); and a behavioral screening tool, the Strength and Difficulties Questionnaire (SDQ). KEY
FINDINGS: HRQOL was significantly lower for children with Dravet syndrome compared to normative data (p < 0.001). A cross-sectional evaluation of measures across different age groups revealed that PedsQL generic core and cognitive function scales decreased in older age categories, indicating worse HRQOL (p < 0.001). Assessment of epilepsy severity demonstrated that symptoms were rated very severe in 10 (6%) of 162 cases, somewhat severe in 78 (48%) of 162, moderate in 51 (32%) of 162, and mild in 23 (14%) of 162 cases. The epilepsy severity correlated significantly with the IPES total impact score (r = 0.466, p < 0.001, n = 162). The IPES total impact scores in the Dravet group (n = 162) were significantly higher than scores measured in the original validation sample of epileptic children with and without learning difficulties (± SD) (21.0 ± 8.7 vs. 11.6 ± 5.4, t = 8.95, p < 0.001, n = 46). On the SDQ, 35% of children scored in the abnormal range for "conduct problems," 66% for "hyperactivity/ inattention," and 76% for "peer relationships." Regression analysis revealed that young age at seizure onset (p = 0.019), presence of myoclonic seizures (p = 0.029), motor disorder (p = 0.048), learning difficulties (p = 0.002), epilepsy severity (p < 0.001), and behavioral difficulties (p < 0.001) each independently predicted poorer HRQOL. Behavioral problems such as hyperactivity/inattention were the strongest predictors of poorer HRQOL. SIGNIFICANCE: This is the first comprehensive study of HRQOL in an etiologically well-defined epilepsy syndrome. HRQOL in Dravet syndrome depends on a series of independent factors including seizure control, behavior, cognitive, and motor problems. Identification of specific comorbidities in Dravet syndrome will facilitate a distinct and multidisciplinary approach to management, addressing seizure control, behavior problems, cognitive difficulties, and motor impairment. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668444     DOI: 10.1111/j.1528-1167.2011.03129.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

1.  Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome.

Authors:  Chao Tai; Yasuyuki Abe; Ruth E Westenbroek; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  Incidence of Dravet Syndrome in a US Population.

Authors:  Yvonne W Wu; Joseph Sullivan; Sharon S McDaniel; Miriam H Meisler; Eileen M Walsh; Sherian Xu Li; Michael W Kuzniewicz
Journal:  Pediatrics       Date:  2015-10-05       Impact factor: 7.124

Review 3.  Treatment Strategies for Dravet Syndrome.

Authors:  Kelly G Knupp; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 4.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

5.  Early-life febrile seizures worsen adult phenotypes in Scn1a mutants.

Authors:  Stacey B B Dutton; Karoni Dutt; Ligia A Papale; Sandra Helmers; Alan L Goldin; Andrew Escayg
Journal:  Exp Neurol       Date:  2017-04-01       Impact factor: 5.330

Review 6.  Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.

Authors:  An-Sofie Schoonjans; Lieven Lagae; Berten Ceulemans
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

7.  Dravet Syndrome-The Polish Family's Perspective Study.

Authors:  Justyna Paprocka; Anita Lewandowska; Piotr Zieliński; Bartłomiej Kurczab; Ewa Emich-Widera; Tomasz Mazurczak
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

8.  Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype.

Authors:  Lisa Ouss; Dorothee Leunen; Jacques Laschet; Nicole Chemaly; Giulia Barcia; Emma M Losito; Aveline Aouidad; Zoe Barrault; Isabelle Desguerre; Delphine Breuillard; Rima Nabbout
Journal:  Epilepsia Open       Date:  2018-12-20

9.  Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants.

Authors:  Joseph D Symonds; Katherine S Elliott; Jay Shetty; Martin Armstrong; Andreas Brunklaus; Ioana Cutcutache; Louise A Diver; Liam Dorris; Sarah Gardiner; Alice Jollands; Shelagh Joss; Martin Kirkpatrick; Ailsa McLellan; Stewart MacLeod; Mary O'Regan; Matthew Page; Elizabeth Pilley; Daniela T Pilz; Elma Stephen; Kirsty Stewart; Houman Ashrafian; Julian C Knight; Sameer M Zuberi
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

10.  Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission.

Authors:  Sung Han; Chao Tai; Ruth E Westenbroek; Frank H Yu; Christine S Cheah; Gregory B Potter; John L Rubenstein; Todd Scheuer; Horacio O de la Iglesia; William A Catterall
Journal:  Nature       Date:  2012-08-22       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.